229 related articles for article (PubMed ID: 37467321)
1. TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells.
Collins SM; Alexander KA; Lundh S; Dimitri AJ; Zhang Z; Good CR; Fraietta JA; Berger SL
Sci Adv; 2023 Jul; 9(29):eadh2605. PubMed ID: 37467321
[TBL] [Abstract][Full Text] [Related]
2. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8
Seo H; Chen J; González-Avalos E; Samaniego-Castruita D; Das A; Wang YH; López-Moyado IF; Georges RO; Zhang W; Onodera A; Wu CJ; Lu LF; Hogan PG; Bhandoola A; Rao A
Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12410-12415. PubMed ID: 31152140
[TBL] [Abstract][Full Text] [Related]
3. TET2 guards against unchecked BATF3-induced CAR T cell expansion.
Jain N; Zhao Z; Feucht J; Koche R; Iyer A; Dobrin A; Mansilla-Soto J; Yang J; Zhan Y; Lopez M; Gunset G; Sadelain M
Nature; 2023 Mar; 615(7951):315-322. PubMed ID: 36755094
[TBL] [Abstract][Full Text] [Related]
4. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Fraietta JA; Nobles CL; Sammons MA; Lundh S; Carty SA; Reich TJ; Cogdill AP; Morrissette JJD; DeNizio JE; Reddy S; Hwang Y; Gohil M; Kulikovskaya I; Nazimuddin F; Gupta M; Chen F; Everett JK; Alexander KA; Lin-Shiao E; Gee MH; Liu X; Young RM; Ambrose D; Wang Y; Xu J; Jordan MS; Marcucci KT; Levine BL; Garcia KC; Zhao Y; Kalos M; Porter DL; Kohli RM; Lacey SF; Berger SL; Bushman FD; June CH; Melenhorst JJ
Nature; 2018 Jun; 558(7709):307-312. PubMed ID: 29849141
[TBL] [Abstract][Full Text] [Related]
5. The Transcription Factor Tox2 Drives T Follicular Helper Cell Development via Regulating Chromatin Accessibility.
Xu W; Zhao X; Wang X; Feng H; Gou M; Jin W; Wang X; Liu X; Dong C
Immunity; 2019 Nov; 51(5):826-839.e5. PubMed ID: 31732165
[TBL] [Abstract][Full Text] [Related]
6. T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy.
Zebley CC; Youngblood B
Trends Immunol; 2023 Jun; 44(6):397-398. PubMed ID: 36959018
[TBL] [Abstract][Full Text] [Related]
7. TET2, tumor control, and CAR T cell hyperproliferation.
Dash B; Hogan PG
Trends Cancer; 2023 Jul; 9(7):521-523. PubMed ID: 37173187
[TBL] [Abstract][Full Text] [Related]
8. TOX2 regulates human natural killer cell development by controlling T-BET expression.
Vong QP; Leung WH; Houston J; Li Y; Rooney B; Holladay M; Oostendorp RA; Leung W
Blood; 2014 Dec; 124(26):3905-13. PubMed ID: 25352127
[TBL] [Abstract][Full Text] [Related]
9. Implications of TET2 in CAR-T Cell Activity and Target Response to CAR-T Cell Therapy: Lessons Learned from T Cells.
Pasca S; Jurj A; Constantinescu C; Zdrenghea M; Tomuleasa C
Crit Rev Immunol; 2021; 41(1):13-21. PubMed ID: 33822522
[TBL] [Abstract][Full Text] [Related]
10. Coexpression of
Xu T; Wang C; Chen X; Bai J; Wang E; Sun M
Immunotherapy; 2022 Dec; 14(18):1457-1466. PubMed ID: 36597720
[TBL] [Abstract][Full Text] [Related]
11. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
12. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
[TBL] [Abstract][Full Text] [Related]
13. Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction.
Jiang P; Zhang Z; Hu Y; Liang Z; Han Y; Li X; Zeng X; Zhang H; Zhu M; Dong J; Huang H; Qian P
Leukemia; 2022 Nov; 36(11):2656-2668. PubMed ID: 35962059
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
15. Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies.
Beider K; Itzhaki O; Schachter J; Grushchenko-Polaq AH; Voevoda-Dimenshtein V; Rosenberg E; Ostrovsky O; Devillers O; Shapira Frommer R; Zeltzer LA; Toren A; Jacoby E; Shimoni A; Avigdor A; Nagler A; Besser MJ
Cells; 2022 Mar; 11(7):. PubMed ID: 35406703
[TBL] [Abstract][Full Text] [Related]
16. Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers.
Tessema M; Yingling CM; Grimes MJ; Thomas CL; Liu Y; Leng S; Joste N; Belinsky SA
PLoS One; 2012; 7(4):e34850. PubMed ID: 22496870
[TBL] [Abstract][Full Text] [Related]
17. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity.
Shen L; Xiao Y; Zhang C; Li S; Teng X; Cui L; Liu T; Wu N; Lu Z
Cancer Lett; 2022 Jul; 538():215710. PubMed ID: 35489446
[TBL] [Abstract][Full Text] [Related]
18. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
19.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.
Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q
J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
